Elfetabart drozuntecan
Antibody–drug conjugate
Also known as DB-1311, BNT324
Evidence outlook · registrational
Metastatic Castration-Resistant Prostate Cancer: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2031-02.
Also in development:Non-Small Cell Lung Cancer
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07365995 NCT07365995 · Metastatic Castration-resistant Prostate Cancer Registry: NCT07365995 | 3 | rPFS assessed by BICR (From randomization to end of study, i.e., up to 58 months); OS (From randomization to end of study, i.e., up to 58 months) 2031-02 | In progress: results expected 1 Feb 2031 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
Other B7-H3 drugs
7MW3711, Ifinatamab Deruxtecan, Risvutatug rezetecan, Tambotatug pelitecan, 177Lu-BetaBart and 1 more. Compare all 7 B7-H3 drugs
6 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Metastatic Castration-Resistant Prostate Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Elfetabart Drozuntecan: this drug | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Olaparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Rucaparib | Approved | Small molecule | PARP (poly ADP-ribose polymerase) enzymes, PARP1/2 | Partial signal | No reviewed efficacy summary in this indication | |
| Talazoparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Fluzoparib | Phase 3 | Small molecule | PARP (poly ADP-ribose polymerase), specifically PARP-1 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-4357 | Phase 3 | Undisclosed | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| Ifinatamab Deruxtecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Mevrometostat | Phase 3 | Small molecule | EZH2 | not yet graded | No reviewed efficacy summary in this indication | |
| Opevesostat | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Pasritamig | Phase 3 | Multispecific antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Zadavotide Guraxetan | Phase 3 | Radioconjugate (actinium-225) | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| Luxdegalutamide | Phase 2 | Small molecule | Androgen receptor, Androgen receptor (degrader) | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-969 | Phase 1 | Undisclosed | PSMA / STEAP1 | not yet graded | No reviewed efficacy summary in this indication | |
| AKY-2519 | Phase 1 | Radiopharmaceutical | B7-H3-targeted radioligand therapy | not yet graded | No reviewed efficacy summary in this indication | |
| BPX-601 | Phase 1 | Cell therapy | PSCA | not yet graded | No reviewed efficacy summary in this indication | |
| RG6852 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Elfetabart drozuntecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.